

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALZW1648

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADO
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	19	MAY 23	GBFULL enhanced with patent drawing images
NEWS	20	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	21	MAY 26	STN User Update to be held June 6 and June 7 at the SLA 2005 Annual Conference
NEWS	22	JUN 06	STN Patent Forums to be held in June 2005
NEWS	23	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:34:02 ON 09 JUN 2005

=> INDEX bioscience pharmacology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:34:31 ON 09 JUN 2005

83 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> HBV Pre-S1 antibod?
36 FILE DGENE
27 FILES SEARCHED...
55 FILES SEARCHED...
1 FILE WPIDS
1 FILE WPINDEX

3 FILES HAVE ONE OR MORE ANSWERS, 83 FILES SEARCHED IN STNINDEX

L1 QUE HBV PRE-S1 ANTIBOD?

=> d rank
F1 36 DGENE
F2 1 WPIDS
F3 1 WPINDEX

=> file wpids wpindex
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.13	4.34

FULL ESTIMATED COST

FILE 'WPIDS' ENTERED AT 14:38:34 ON 09 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 8 JUN 2005 <20050608/UP>
MOST RECENT DERWENT UPDATE: 200536 <200536/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-revision/>
FOR DETAILS. <<<

=> hbv pre-s1 antibod?
936 HBV
6 HBVS
938 HBV
(HBV OR HBVS)
174656 PRE
1593 PRES
176206 PRE
(PRE OR PRES)
41677 S1
68706 ANTIBOD?
L2 1 HBV PRE-S1 ANTIBOD?
(HBV(W) PRE(W) S1(W) ANTIBOD?)

=> d bib

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1995-068451 [10] WPIDS
DNN N1995-054347 DNC C1995-030215
TI Chimeric vaccinia virus expressing hepatitis B large antigen - without
the myristoylation site and related antibodies, for diagnosis, therapy and
vaccines.
DC B04 D16 S03
IN DORNER, F; FALKNER, F; PFLEIDERER, M
PA (IMMO) IMMUNO AG; (BAXT) BAXTER AG
CYC 14
PI EP 637631 A2 19950208 (199510)* GE 38
R: AT BE CH DE DK ES FR GB IT LI NL SE
CA 2129156 A 19950131 (199517)
EP 637631 A3 19960821 (199641)
US 6004561 A 19991221 (200006)
US 6077691 A 20000620 (200035)
AT 9401504 A 20020415 (200234)
AT 409863 B 20021015 (200277)
ADT EP 637631 A2 EP 1994-111872 19940729; CA 2129156 A CA 1994-2129156
19940729; EP 637631 A3 EP 1994-111872 19940729; US 6004561 A Cont of US
1993-99351 19930730, Div ex US 1995-440682 19950515, US 1997-797629
19970207; US 6077691 A Cont of US 1993-99351 19930730, Div ex US
1995-440682 19950515, US 1997-796415 19970206; AT 9401504 A AT 1994-1504
19940729; AT 409863 B AT 1994-1504 19940729
FDT AT 409863 B Previous Publ. AT 9401504
PRAI US 1993-99351 19930730; US 1995-440682 19950515;
US 1997-797629 19970207; US 1997-796415 19970206

=> FIL STNGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
7.70	12.04

FILE 'STNGUIDE' ENTERED AT 14:39:18 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 3, 2005 (20050603/UP).

=> d ibib abs ti
YOU HAVE REQUESTED DATA FROM FILE 'WPIDS' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1995-068451 [10] WPIDS
DOC. NO. NON-CPI: N1995-054347
DOC. NO. CPI: C1995-030215
TITLE: Chimeric vaccinia virus expressing hepatitis B large
antigen - without the myristoylation site and related
antibodies, for diagnosis, therapy and vaccines.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): DORNER, F; FALKNER, F; PFLEIDERER, M
PATENT ASSIGNEE(S): (IMMO) IMMUNO AG; (BAXT) BAXTER AG
COUNTRY COUNT: 14
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 637631	A2	19950208	(199510)*	GE	38
R: AT BE CH DE DK ES FR GB IT LI NL SE					
CA 2129156	A	19950131	(199517)		
EP 637631	A3	19960821	(199641)		
US 6004561	A	19991221	(200006)		
US 6077691	A	20000620	(200035)		
AT 9401504	A	20020415	(200234)		
AT 409863	B	20021015	(200277)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 637631	A2	EP 1994-111872	19940729
CA 2129156	A	CA 1994-2129156	19940729
EP 637631	A3	EP 1994-111872	19940729
US 6004561	A	Cont of	US 1993-99351
		Div ex	US 1995-440682
			US 1997-797629
US 6077691	A	Cont of	US 1993-99351
		Div ex	US 1995-440682
			US 1997-796415
AT 9401504	A	AT 1994-1504	19940729
AT 409863	B	AT 1994-1504	19940729

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AT 409863	B Previous Publ.	AT 9401504

PRIORITY APPLN. INFO: US 1993-99351 19930730; US
1995-440682 19950515; US
1997-797629 19970207; US
1997-796415 19970206

AN 1995-068451 [10] WPIDS

AB EP 637631 A UPAB: 19950314

Chimaeric vaccinia virus (A) comprises a promoter functionally coupled to a sequence (I) encoding a region of a large antigen (Ag) of hepatitis B virus (HBV) including at least the pre S1-B- or T-cell epitopes but lacking the myristoylation site of the pre S1 region. Also new are (1) synthesis of Ag by culturing eukaryotic cells transformed with (A); (2) Ag

produced this way; (3) vaccines containing this Ag; (4) anti-HBV pre S1-antibodies (Ab) made by immunisation with Ag.

USE - Ag and Ab are variously useful as diagnostic reagents, therapeutics and vaccines (able to induce a response in some patients who do not respond to standard HBV vaccines). Ab can also be used to prepare immunotoxins.

ADVANTAGE - Infected cells produce large amts. of pre S1 protein; deletion of the myristoylation site provided a higher level of expression and facilitates purifcn. and isolation of protein. Ag can now be expressed in cells where HBV replication naturally occurs, so it is correctly processed, and the vaccinia system is unable to express small or medium antigens from internal promoters. The immunogenic potential of Ag can be increased by coupling to an immunopotentiator or by increasing the number of pre S1 sequences in (I).

Dwg.1/14

TI Chimeric vaccinia virus expressing hepatitis B large antigen - without the myristoylation site and related antibodies, for diagnosis, therapy and vaccines.

=> d his

(FILE 'HOME' ENTERED AT 14:34:02 ON 09 JUN 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:34:31 ON 09 JUN 2005
SEA HBV PRE-S1 ANTIBOD?

36 FILE DGENE
1 FILE WPIDS
1 FILE WPINDEX
L1 QUE HBV PRE-S1 ANTIBOD?

L2 FILE 'WPIDS' ENTERED AT 14:38:34 ON 09 JUN 2005
1 HBV PRE-S1 ANTIBOD?

FILE 'STNGUIDE' ENTERED AT 14:39:18 ON 09 JUN 2005

FILE 'WPIDS' ENTERED AT 14:41:03 ON 09 JUN 2005

FILE 'STNGUIDE' ENTERED AT 14:41:05 ON 09 JUN 2005

=>

Connection closed by remote host

Dialog search history

B 155, 189, 73, 222, 5, 71, 357

s antibod? or immune (w) response or receptor?

s (Hepatitis(w) B or HBV) (w) surface (w) antigen (w) pre(w)S

s S1 and S2

S S3 not py ≥ 2000

rd

s KR 127

S au = (

6/K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

14714737 PMID: 12659834

The influence of glycosylation on secretion, stability, and immunogenicity of recombinant HBV pre-S antigen synthesized in *Saccharomyces cerevisiae*.

Lee Jeewon; Park Jin-Seung; Moon Je-Young; Kim Ki-Yong; Moon Hong-Mo
Department of Chemical and Biological Engineering, Korea University,
Anam-Dong, Sungbuk-Ku, Seoul 136-701, Republic of Korea. leejuw@korea.ac.kr
Biochemical and biophysical research communications (United States) Apr
4 2003, 303 (2) p427-32, ISSN 0006-291X Journal Code: 0372516

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... degrees (Asn15Gln and Asn123Gln). An N-terminus sequence (Ser5-Ala28) of human interleukin 1 beta (hIL-1 beta) was used as synthetic prosequence of recombinant HBV surface antigen (pre-S), secreted from *S. cerevisiae*. The expression cassette comprised the signal peptide of the killer toxin of *Kluyveromyces lactis*, the synthetic prosequence above, KEX2 dibasic endopeptidase...

... glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing antibodies. This problem was overcome by eliminating both of the N-glycosylation signals. Despite enhanced immunogenicity, the recombinant pre-S1 degrees S2 degrees showed two major...

Chemical Name: Hepatitis B Surface Antigens; Interleukin-1; Pre-S protein, Duck hepatitis B virus; Protein Precursors; Recombinant Proteins; Viral Envelope Proteins; presurface protein 1, hepatitis B surface antigen; presurface protein 2, hepatitis B surface antigen

6/K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

07599319 PMID: 2425034

Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre-S (2) region synthetic peptide.

Milich D R; McLachlan A; Chisari F V; Thornton G B

Journal of experimental medicine (UNITED STATES) Aug 1 1986, 164 (2) p532-47, ISSN 0022-1007 Journal Code: 2985109R

Contract/Grant No.: AI00585; AI; NIAID; AI20001; AI; NIAID; AI20720; AI; NIAID

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre-S (2) region synthetic peptide.

We have examined T cell recognition of a hepatitis B surface antigen (HBsAg), pre-S(2)-region synthetic peptide, p120-145, in terms of fine specificity, H-2-linked genetic influences, comparison to antibody binding, and relevance to T cell recognition of the native protein. We

showed that the **immune** response to the synthetic peptide is regulated by H-2-linked genes, but that the pattern of H-2 restriction differed from that observed for the...

... cell and B cell recognition sites were identified on the synthetic peptide p120-145. T cell recognition is focussed on the NH2-terminal sequence, and **antibody** (B cell) recognition is focussed on the COOH-terminal sequence. The fine specificity of T cell recognition of p120-145 was defined by a single...

...strains; whereas separate T or B cell peptide determinants are minimally immunogenic. Furthermore, the synthetic T cell recognition site can prime T cell help for **antibody** production to the synthetic B cell site, which is crossreactive with the native pre-S(2) region of HBsAg/p33 particles. This system provides evidence...

; Amino Acid Sequence; Animals; **Antibodies** , Viral--biosynthesis--BI; Cross Reactions; Epitopes--immunology--IM; H-2 Antigens--genetics--GE; Mice ; Mice, Inbred C3H; Mice, Inbred C57BL

Chemical Name: **Antibodies** , Viral; Epitopes; H-2 Antigens; Hepatitis B Surface Antigens; Peptide Fragments; Viral Proteins

6/K/3 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

12014847 EMBASE No: 2003125765

The influence of glycosylation on secretion, stability, and immunogenicity of recombinant HBV pre-S antigen synthesized in *Saccharomyces cerevisiae*

Lee J.; Park J.-S.; Moon J.-Y.; Kim K.-Y.; Moon H.-M.

J. Lee, Dept. of Chem./Biol. Engineering, Korea University, Anam-Dong, Sungbuk-Ku, Seoul 136-701 South Korea

AUTHOR EMAIL: leejw@korea.ac.kr

Biochemical and Biophysical Research Communications (BIOCHEM. BIOPHYS.

RES. COMMUN.) (United States) 04 APR 2003, 303/2 (427-432)

CODEN: BBRCA ISSN: 0006-291X

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 22

...and pre-S1degreesS2degrees (Asn15Gln and Asn123Gln). An N-terminus sequence (Ser5-Ala28) of human interleukin 1beta (hIL-1beta) was used as synthetic prosequence of recombinant **HBV surface antigen (pre - S)**, secreted from *S. cerevisiae*. The expression cassette comprised the signal peptide of the killer toxin of *Kluyveromyces lactis*, the synthetic prosequence above, KEX2 dibasic endopeptidase...

...glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing **antibodies** . This problem was overcome by eliminating both of the N-glycosylation signals. Despite enhanced immunogenicity, the recombinant pre-S1degreesS2degrees showed two major problems: (1) inefficient...

DRUG DESCRIPTORS:

proteinase--endogenous compound--ec; neutralizing **antibody** --endogenous compound--ec; glycan derivative

6/K/4 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

03107183 EMBASE No: 1986219760

Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre - S (2) region synthetic peptide

Milich D.R.; McLachlan A.; Chisari F.V.; Thornton G.B.

Department of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolla, CA 92037 United States

Journal of Experimental Medicine (J. EXP. MED.) (United States) 1986, 164/2 (532-547)

CODEN: JEMEA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre - S (2) region synthetic peptide

We have examined T cell recognition of a **hepatitis B surface antigen** (HBsAg), pre-S(2)-region synthetic peptide, p120-145, in terms of fine specificity, H-2-linked genetic influences, comparison to **antibody** binding, and relevance to T cell recognition of the native protein. We showed that the **immune response** to the synthetic peptide is regulated by H-2-linked genes, but that the pattern of H-2-restriction differed from that observed for the...

...and B cell recognition sites were identified on the synthetic peptide p120-145. T cell recognition is focussed on the NHinf 2-terminal sequence, and **antibody** (B cell) recognition is focussed on the COOH-terminal sequence. The fine specificity of T cell recognition of p120-145 was defined by a single...

...strains, whereas separate T or B cell peptide determinants are minimally immunogenic. Furthermore, the synthetic T cell recognition site can prime T cell help for **antibody** production to the synthetic B cell site, which is crossreactive with the native pre-S(2) region of HBsAg/p33 particles. This system provides evidence...

DRUG DESCRIPTORS:

* **hepatitis b surface antigen** ; *synthetic peptide

MEDICAL DESCRIPTORS:

*b lymphocyte; *h2 restriction; *h2 system; *t lymphocyte; * **antibody** production; * **immune response**

6/K/5 (Item 1 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014319761 BIOSIS NO.: 200300274294

The influence of glycosylation on secretion, stability, and immunogenicity of recombinant HBV pre-S antigen synthesized in Saccharomyces cerevisiae.

AUTHOR: Lee Jeewon (Reprint); Park Jin-Seung; Moon Je-Young; Kim Ki-Yong; Moon Hong-Mo

AUTHOR ADDRESS: Department of Chemical and Biological Engineering, Korea University, Anam-Dong, Sungbuk-Ku, Seoul, 136-701, South Korea**South Korea

AUTHOR E-MAIL ADDRESS: leejew@korea.ac.kr

JOURNAL: Biochemical and Biophysical Research Communications 303 (2): p 427-432 April 4, 2003 2003

MEDIUM: print

ISSN: 0006-291X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: pre-S1degreesS2degree (Asn15Gln and Asn123Gln). An N-terminus sequence (Ser5-Ala28) of human interleukin 1beta (hIL-1beta) was used as synthetic pro-sequence of recombinant **HBV surface antigen (pre - S)**, secreted from *S. cerevisiae*. The expression cassette comprised the signal peptide of the killer toxin of *Kluyveromyces lactis*, the synthetic prosequence above, KEX2 dibasic endopeptidase...

...glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing **antibodies**. This problem was overcome by eliminating both of the N-glycosylation signals. Despite enhanced immunogenicity, the recombinant pre-S1degreesS2degree showed two major problems: (1) inefficient...

6/K/6 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0005468286 BIOSIS NO.: 198733074891

HUMAN SERUM ALBUMIN AND THE ENIGMA OF HEPATITIS TYPE B

AUTHOR: HELLSTROM U B (Reprint); SYLVAN S P E

AUTHOR ADDRESS: ELIAS BENGTTSSON RES UNIT, DEP INFECT DIS, KAROLINSKA INST, ROSLAGSTULL HOSP, BOX 5651, S-11489 STOCKHOLM, SWED**SWEDEN

JOURNAL: Journal of Medical Virology 21 (4): p106A 1987

CONFERENCE/MEETING: 1987 INTERNATIONAL SYMPOSIUM ON VIRAL HEPATITIS AND LIVER DISEASE, LONDON, ENGLAND, UK, MAY 1987. J MED VIROL.

ISSN: 0146-6615

DOCUMENT TYPE: Meeting

RECORD TYPE: Citation

LANGUAGE: ENGLISH

DESCRIPTORS: ABSTRACT HEPATITIS B VIRUS **HEPATITIS B SURFACE ANTIGEN**
PRE - S GENE ANTIBODY T-CELL B-CELL HEPATOCYTE

6/K/7 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0005246402 BIOSIS NO.: 198682092789

NONOVERLAPPING T AND B CELL DETERMINANTS ON AN HEPATITIS B SURFACE ANTIGEN PRE - S -2 REGION SYNTHETIC PEPTIDE

AUTHOR: MILICH D R (Reprint); MCLACHLAN A; CHISARI F V; THORNTON G B

AUTHOR ADDRESS: DEP BASIC CLINICAL RES, SCRIPPS CLINIC AND RES FOUND, 10666 NORTH TORREY PINES ROAD, LA JOLLA, CA 92037, USA**USA

JOURNAL: Journal of Experimental Medicine 164 (2): p532-547 1986

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

NONOVERLAPPING T AND B CELL DETERMINANTS ON AN HEPATITIS B SURFACE ANTIGEN PRE - S -2 REGION SYNTHETIC PEPTIDE

ABSTRACT: We have examined T cell recognition of a **hepatitis B surface antigen** (HBsAg), pre-S(2)-region synthetic peptide, p120-145, in terms of fine specificity, H-2-linked genetic influences, comparison to

antibody binding, and relevance to T cell recognition of the native protein. We showed that the **immune response** to the synthetic peptide is regulated by H-2-linked genes, but that the pattern of H-2 restriction differed from that observed for the...

...cell and B cell recognition sites were identified on the synthetic peptide p120-145. T cell recognition is focused on the NH₂-terminal sequence, and **antibody** (B cell) recognition is focused on the COOH-terminal sequence. The fine specificity of T cell recognition of p120-145 was defined by a single...

...strains, whereas separate T or B cell peptide determinants are minimally immunogenic. Furthermore, the synthetic T cell recognition site can prime T cell help for **antibody** production to the synthetic B cell site, which is crossreactive with the native pre-S(2) region of HBsAg/p33 particles. This system provides evidence...

DESCRIPTORS: MOUSE **ANTIBODY** BINDING RECOGNITION SITE

6/K/8 (Item 1 from file: 71)

DIALOG(R) File 71:ELSEVIER BIOBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

02294892

2003078567

The influence of glycosylation on secretion, stability, and immunogenicity of recombinant HBV pre-S antigen synthesized in *Saccharomyces cerevisiae*

Lee J.; Park J.-S.; Moon J.-Y.; Kim K.-Y.; Moon H.-M.

ADDRESS: J. Lee, Dept. of Chem./Biol. Engineering, Korea University,

Anam-Dong, Sungbuk-Ku, Seoul 136-701, South Korea

EMAIL: leejw@korea.ac.kr

Journal: Biochemical and Biophysical Research Communications, 303/2

(427-432), 2003, United States

PUBLICATION DATE: April 4, 2003

CODEN: BBRCA

ISSN: 0006-291X

DOCUMENT TYPE: Article

LANGUAGES: English SUMMARY LANGUAGES: English

NO. OF REFERENCES: 22

DESCRIPTORS:

HBV pre-S; Secretion; N-glycosylation; Immunogenicity; Proteolysis

CLASSIFICATION CODE AND DESCRIPTION:

86.7.4.1.- IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNITY TO INFECTION /

Medical and Veterinary Virology / Diagnosis

86.7.4.9 - IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNITY TO INFECTION /

Medical and Veterinary Virology / Antigens

...and pre-S1degreesS2degrees (Asn15Gln and Asn123Gln). An N-terminus sequence (Ser5-Ala28) of human interleukin 1beta (hIL-1beta) was used as synthetic prosequence of recombinant **HBV surface antigen (pre - S)**, secreted from *S. cerevisiae*. The expression cassette comprised the signal peptide of the killer toxin of *Kluyveromyces lactis*, the synthetic prosequence above, KEX2 dibasic endopeptidase...

...glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing **antibodies**. This problem was overcome by eliminating both of the N-glycosylation signals. Despite enhanced immunogenicity, the recombinant pre-S1degreesS2degrees showed two major problems: (1) inefficient...

6/K/9 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0114932 DBR Accession No.: 91-02574

Expression of hepatitis B virus antigens in attenuated Salmonellae for oral immunization - core antigen and surface antigen gene cloning and expression in Salmonella typhimurium and Salmonella dublin; oral live recombinant vaccine construction (conference paper)

AUTHOR: Schoedel F; Will H

CORPORATE AFFILIATE: Max-Planck-Inst.Biochem.

CORPORATE SOURCE: Max-Planck-Institut fuer Biochemie, 8033 Martinsried, Germany.

JOURNAL: Res.Microbiol. (141, 7-8, 831-37) 1990

CODEN: RMCREW

LANGUAGE: English

...ABSTRACT: anti-LT-B immune responses when fed to mice. To combine the protective potential and high immunogenicity of HBV core antigen (HBcAg) with induction of **antibodies** to **HBV surface antigen (pre - S)**, vectors encoding hybrid HBcAg/pre-S particles were constructed, where the pre-S epitopes were surface exposed. Stable constitutive high level expression of the hybrid...

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

?